Elicio Therapeutics, Inc.
ELTX
$8.05
$0.516.76%
NASDAQ
| 09/30/2025 | 06/30/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | -2.56% | 4.29% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -20.28% | -6.01% | |||
| Operating Income | 20.28% | 6.01% | |||
| Income Before Tax | 4.53% | 5.78% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | 4.53% | 5.78% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 4.53% | 5.78% | |||
| EBIT | 20.28% | 6.01% | |||
| EBITDA | 20.34% | 6.04% | |||
| EPS Basic | 8.15% | 24.02% | |||
| Normalized Basic EPS | 11.63% | 21.04% | |||
| EPS Diluted | 8.15% | 24.02% | |||
| Normalized Diluted EPS | 11.63% | 21.04% | |||
| Average Basic Shares Outstanding | 3.94% | 24.01% | |||
| Average Diluted Shares Outstanding | 3.94% | 24.01% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||